10 February 2015 in Journal of Chemical Theory and Computation
An efficient molecular simulation methodology has been developed for the evaluation of the druggability (ligandability) of a protein. Previously proposed techniques were designed to assess the druggability of crystallographic structures and cannot be tightly coupled to molecular dynamics (MD) simulations. By contrast, the present approach, JEDI (Just Exploring Druggability at protein Interfaces), features a druggability potential made of a combination of empirical descriptors that can be collected “on-the-fly” during MD simulations. Extensive validation studies indicate that JEDI analyses discriminate druggable and nondruggable protein binding site conformations with accuracy similar to alternative methodologies, and at a fraction of the computational cost. Since the JEDI function is continuous and differentiable, the druggability potential can be used as collective variable to rapidly detect cryptic druggable binding sites in proteins with a variety of MD free energy methods. Protocols for applications to flexible docking problems are outlined.
15 April 2026 in ChemRxiv
The growing interest in studying modified and cyclic peptides is constrained by limitations in how their chemical information is encoded, represented, and analysed. Traditional sequence formats such as FASTA only allow working with linear and natural peptides. HELM and BILN formats provide more versatile and extendible notation systems for the representation of peptides with non-natural monomers or cyclic arrangements. HELM is a notation that uses a database as a source of monomers where these are defined on their structure, identifier, and attachment points. While structural representations are canonicalized using established methods, there is currently no widely accepted convention for naming peptide monomers. In this manuscript, we develop on top of the guidelines proposed by Pistoia Alliance for the naming of non-natural amino acids for their representation using HELM. Our nomenclature extends on modifications of side chains and backbone, naming of homo amino acids and peptoids, and resolves ambiguous cases using a combination of systematic and pragmatic rules.
5 July 2026 in Journal of Chemical Information and Modeling
The pharmaceutical industry’s shift toward new drug modalities, including therapeutic peptides, modified oligonucleotides, and antibody–drug conjugates, has exposed fundamental gaps in cheminformatics infrastructure. Unlike small molecules, which benefit from mature representation standards and reliable data exchange, new modalities lack robust and interoperable systems capable of capturing their structural and chemical complexity. Drawing on our experience at AstraZeneca, we examine these challenges across peptides, oligonucleotides, and ADCs, focusing on the limitations of current approaches, particularly HELM. We show that these limitations arise from both technical constraints, as new modalities exceed the scope of purely atomistic or sequence-based representations, and organizational gaps, including unresolved standardization and governance. We argue that local solutions exacerbate fragmentation, and that vendor- and community-driven standards, open implementations, and stronger governance are required to enable standardized and interoperable chemical information systems for next-generation therapeutics.